Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6071612 | 0.93 | SLC18A3 (0.54) | SLC18A3MAPK1C1SCHRNA7 | |
| Trifluoroacetic Acid SCHEMBL6072334 | 0.89 | SLC18A3 (0.49) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6072038 | 0.88 | SLC18A3 (0.49) | SLC18A3C1S | |
| Trifluoroacetic Acid SCHEMBL6071354 | 0.87 | SLC18A3 (0.48) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6071723 | 0.87 | ALDH1A1 (0.50) | SLC18A3MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6071855 | 0.85 | SLC18A3 (0.45) | SLC18A3MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6071717 | 0.84 | TTR (0.46) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL5814484 | 0.84 | TTR (0.46) | SLC18A3 | |
| Trifluoroacetic Acid SCHEMBL6071803 | 0.83 | KDM4E (0.45) | SLC18A3MAPK1 | |
| Trifluoroacetic Acid SCHEMBL6071817 | 0.82 | FAAH (0.43) | SLC18A3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189628-A1 | Compounds useful as chemokine receptor antagonists | ACKR3, CCR5, CXCR2 | SLC18A3 2263/4885MAPK1 996/4885C1S 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.